Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why hVIVO (LSE:HVO) Expands Human Challenge Clinical Trial Facilities for Global Biopharma Clients

hVIVO plc (LSE:HVO) has solidified its global marketLeadershipin human challenge clinical trials, completing the operational expansion and commercial ramp-up of its state-of-the-artQuarantinetrial facility in Canary Wharf, London. Quoted on the AIM market of the London Stock Exchange, the specialist contract research organisation (CRO) provides …

Ankur Sharma | 07 October 2026

Why IXICO (LSE:IXI) Deploys Advanced Neuroimaging Analytics Across Global Clinical Trials

IXICO plc (LSE:IXI) is executing a strategic operational recovery, deploying advanced artificial intelligence neuroimaging algorithms and digital biomarker solutions across global biopharmaceutical clinical trials. Quoted on the AIM market of the London Stock Exchange, the medical technology specialist provides automated brain MRI and PET …

Ankur Sharma | 07 October 2026

SkinBioTherapeutics (LSE:SBTX) Shares Fall 7.07%: Can New Leadership Restore Investor Confidence?

• Stock theme:Leadershipstabilisation and recovery from a challenging period.

Ankur Sharma | 07 October 2026

Faron Pharmaceuticals Oy (LSE:FARN) Gains 4.11% Ahead of R&D Day as Bexmarilimab Pipeline Takes Centre Stage

Investor attention is centred on bexmarilimab, the company’s lead macrophage-targeting immunotherapy candidate.

Ankur Sharma | 07 October 2026

ImmuPharma plc (LSE:IMM) Jumps 9.77%: Why the Stock Is in Focus on 7 October 2026

ImmuPharma plc (LSE:IMM) is up 9.77% on 7 October 2026, placing it among the stronger-moving UK-traded shares in the session. The stock is in focus because of renewed speculative interest in the biotechnology company and its clinical-development pipeline after a weak year-to-date share-price performance. …

Ankur Sharma | 07 October 2026

What Is Shaping Worldwide Healthcare Trust's Path Within the FTSE 250 This Autumn (LSE:WWH)

Worldwide Healthcare Trust (LSE:WWH), one of the largest specialist healthcareInvestmenttrusts on the London market, is entering the final months of 2026 with a focus onCapitalmanagement and communication with shareholders. While there have been no major results announcements since the summer, a steady stream of …

Ankur Sharma | 07 October 2026

How Syncona Is Repositioning Its Life Science Portfolio as a FTSE 250 Investment Company (LSE:SYNC)

Syncona (LSE:SYNC), the FTSE 250 life scienceInvestmentcompany that founds, builds and funds European biotechnology businesses, is midway through a significant strategic shift. Its first-quarter update, covering the three months to 30 June 2026, showed a stableBalance Sheetand a portfolio approaching several important clinical milestones, …

Ankur Sharma | 07 October 2026

AOTI Shares Rise 3.25% as Medicare Coverage Proposal Promises to Transform TWO2 Wound Therapy Market (LSE:AOTI)

The California-based company, which listed on AIM in 2024, is approaching what could be the most important regulatory milestone in its history: final Medicare coverage for topical oxygen therapy in the United States.

Ankur Sharma | 07 October 2026

Hemogenyx Pharmaceuticals (LSE:HEMO) Shares Drop 8.96%: What Are Investors Watching in the CAR-T Story?

• Stock theme: Clinical-stage CAR-T development and funding expectations.

Ankur Sharma | 07 October 2026

What Spire Healthcare's Agreed £1bn Takeover Means for Its FTSE 250 Future (LSE:SPI)

Spire Healthcare (LSE:SPI), the largest independent hospital operator in the UK, looks set to leave the FTSE 250 after its board backed aTakeoverfrom a consortium led by its long-standingShareholderToscafund. The deal, agreed in early September after months of negotiation, was followed on 30 September …

Ankur Sharma | 07 October 2026
Support

Hi! How can we help you today?

Loading…